Evogene Ltd. Stock: price and insider trades · United States
1 insider bought €253k of shares over the last 90 days, the latest by RECANATI LEON, filed 13 Aug 2026.
Evogene Ltd.: what insiders have been doing
Headquartered in Rehovot, Israel, Evogene Ltd. is a listed company and traces its origins to 2002. Filings by its managers are published through SEC (Form 4). Between 8 November 2025 and 8 November 2026, 1 insider published 2 filings.
The flow runs one way only: 1 insider bought (2 purchases totalling €600k) and nobody sold on the market. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. One trade stands out by size: a purchase of €347k from Recanati Leon, disclosed on 5 August 2026, or 6.0% of market capitalisation. On the buying side, the filings list 1 senior executive among the declarants.
With 2 filings in twelve months, the company is quieter than the median of 19 filings across the 5,813 companies we follow on the same exchange. Over the whole record (from 2026), the tally stands at 2 purchases and no sales.
The clock since the last published purchase (13 August 2026) now reads 87 days.
For comparison within the same market, see the insider buying recorded at GameStop Corp. and Heico Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Who traded when
BuySaleSince the insiders bought
- -18.3%Entry US$0.60 · Close at T+30 US$0.49
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 460,000 shares@ US$0.6354.38% mcap42.1% of flowOrdinary SharesSEC:0001178913-26-004095:0Canonical exit: 9 Nov 2026 (T+90)
- 800,000 shares@ US$0.506.02% mcap57.9% of flowOrdinary SharesSEC:0001178913-26-003859:0Canonical exit: 2 Nov 2026 (T+90)
2 of 2 declarations
About Evogene Ltd.
Evogene Ltd. is a biotechnology company that utilizes advanced technologies to enhance crops and agricultural products. It focuses on developing innovative solutions for sustainable agriculture.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
